Robert Allen, PhD

home / authors / robert-allen-phd

Allen is the Chief Scientific Officer at Invivyd.

Articles

Invivyd Tracks SARS-CoV-2 Evolution, Prepares for Future Variants

Sophia Abene;Robert Allen, PhD

February 4th 2025

Robert Allen, MD, on variant monitoring, antibody development, and the company's long-term approach to patient care.

Pemgarda Maintains Effectiveness Against Evolving SARS-CoV-2 Variants

Sophia Abene;Robert Allen, PhD

February 3rd 2025

Robert Allen, PhD, discusses how Pemgarda’s stability in targeting the spike protein's receptor-binding domain offers crucial protection, including immunocompromised individuals.

A Monoclonal Antibodies' Prospective Place in the COVID-19 PrEP Market

John Parkinson;Robert Allen, PhD

October 21st 2024

Invivyd’s Chief Scientific Officer Robert Allen, PhD, discusses the company’s pemivibart (Pemgarda) including its administration, how it can be used in concert with vaccines, and how it protects against newer variants.